Rx3 Pharmaceuticals, Inc. Creates New Clinical Advisory Board  
9/26/2006 9:55:01 AM

SAN DIEGO, Sept. 26 /PRNewswire/ -- Rx3 Pharmaceuticals, Inc., an anti-infective drug discovery company, announced today that it has recently created a new Clinical Advisory Board (CAB) to complement its existing group of scientific advisers. Joining the new CAB are John S. Bradley, M.D., Henry Chambers, M.D., Robert Moellering, M.D., and Victor Nizet, M.D.

"These individuals are among the most highly regarded thought leaders in the field of antibacterial drug discovery and development," said Jeff Stein, Ph.D., Chairman of Rx3 Pharmaceuticals as well as Chairman of its current Scientific Advisory Board. "We expect that their deep knowledge and experience will contribute enormously to the Company's goal of developing new treatments for bacterial disease."

Dr. Bradley is Director of the Division of Infectious Diseases at Children's Hospital in San Diego. He is also a member of the FDA's anti-infective drugs advisory committee. Dr. Chambers is Chief of Infectious Diseases at San Francisco General Hospital and also a Professor at UCSF. He has over 100 publications in the areas of drug resistance and bacterial infections and is a reviewer for numerous medical publications. Dr. Moellering is the Shields Warren-Mallinckrodt Professor of Medical Research at Harvard Medical School in the Department of Medicine at Beth Israel Deaconess Medical Center in Boston, Massachusetts. He has been actively involved in laboratory research related to antimicrobials for 30 years and he has over 350 publications in scientific journals. Dr. Nizet is Chief of the Division of Pharmacology & Drug Discovery at UCSD School of Medicine. His award winning research work has been recognized by the Dana-Farber Cancer Institute, the American Heart Association, and the American Lung Association.

More information on each of the four new CAB members can be found on the Company's web site.

About Rx3 Pharmaceuticals

Rx3 Pharmaceuticals is a drug discovery company applying its structure-based drug design technologies to its antimicrobial programs. These programs target novel proteins in validated pathways. For more information, visit

Rx3 Pharmaceuticals, Inc.

CONTACT: John P. Schmid, Chief Financial Officer of Rx3 Pharmaceuticals,Inc., +1-858-452-0370, ext. 105,; or Media, KarenKristofferson, Mentus, Life Science, +1-858-455-5500, ext. 275,, for Rx3 Pharmaceuticals, Inc.